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IDENTIFICATION OF A UNIQUE CORE
DOMAIN OF PAR-4 SUFFICIENT FOR
SELECTIVE APOPTOSIS INDUCTION IN
CANCER CELLS

nosis in both localiZed and disseminated disease. Currently,
there is a 34% chance of recurrence of prostate cancer. The

median time to development of clinical metastasis after bio
chemical recurrence is 8 years. Once treatment resistant

metastatic disease is developed, the median time to death is an
additional 5 years. Pound et al., JAMA (1999) 271: 1591-97.

CROSS-REFERENCE TO RELATED
APPLICATIONS

Another common cancer linked to hormone action is breast
cancer. Current treatments for breast cancer include surgery

This application claims priority under 35 U.S.C. §119 to
US. Provisional Application No. 60/430,669 entitled “Iden

to remove the cancer, radiation therapy, chemotherapy,

ti?cation of a Unique Core Domain of Par-4 Suf?cient for

tation, hormonal therapy, and biological immunotherapy (us

Selective Apoptosis Induction in Cancer Cells” ?led Dec. 4,
2002, the entire content of Which is hereby incorporated by
reference in its entirety.

ing the immune system to ?ght cancer).

peripheral stem cell transplantation, bone marroW transplan
Side effects of cancer therapies are often severe. They

include nausea, vomiting, pain, poor appetite, Wasting,
cachexia, diarrhea, burning in the stomach, stress, planter

IDENTIFICATION OF FEDERAL FUNDING

Warts, nerve death-neuropathy, radiation burns, fatigue, con

stipation, anemia, anxiety, Weakened immune system, dry
The present invention Was supported by NIH/NCI R01
grants CA60872 and CA8451 1 , and therefore the government

may have rights in the invention.

20

FIELD OF THE INVENTION

cally target tumor cells, therefore, appropriately constitutes a
signi?cant area of cancer research. Such molecules With
selective action against tumor cells are valuable not only for

The present invention relates to prostate apoptosis
response-4 (Par-4) mutants Which cause apoptosis in cancer
cells Which are sensitive to Par-4 and also induce apoptosis in

25

their therapeutic potential; but also for their potential appli
cations as tools for dissection of fundamental differences
betWeen normal and cancer cells. Thus, the identi?cation of a

cancer cells Which are resistant to Par-4. The present inven
tion also relates to methods of using the Par-4 mutant to treat
certain cancers, as Well as to kits, vectors, and polypeptides
for same.

skin, bone marroW suppression and hair loss.
An essential feature of anticancer strategies is the selective
action against cancer cells, With little or no damage in?icted
in normal cells. Identi?cation of molecules that can speci?

molecule that can speci?cally target certain types of hormon
ally linked cancers Would be extremely useful.
30

SUMMARY OF THE INVENTION

BACKGROUND OF THE INVENTION

The present invention relates to the unexpected discovery
These mutants/Par-4 may be effective against all cancers.
Cancer causes the death of hundreds of thousands of people

35

each year. Treatments for cancer are not alWays effective.

normal cells. Certain Par-4 mutants have been discovered to
be useful in the treatment of cancer.

Cancer is dif?cult to treat because the development of
cancer is a multistep process involving accumulation of mul

An object of the present invention is to provide a modi?ed

tiple genetic aberrations. Most notable among such alter
ations is the loss of apoptotic responses that normally serve as

40

built in checkpoints against the emergence of cell populations
With dysfunctional traits or the acquisition of prosurvival
mechanisms that override the apoptotic signals. The loss of
apoptotic mechanisms often results in abridged response to
cancer therapy. Therefore, alternate or combinatorial
approaches to kill the cancer cells and induce tumor regres

Par-4 comprising a substitution of least one amino acid resi
due in the amino acid sequence of a precursor Par-4 in at least

one position of naturally produced Par-4, Wherein the modi
?ed Par-4 is effective in reducing the siZe of tumors resistant
to Par-4. The modi?ed Par-4 is preferably 1-204, 137-221,
137-213,137-198 or 137-195.
45

Another object of the present invention provides an iso
lated nucleic acid sequence fragment comprising at least 500
contiguous nucleotides including a polymorphic site com
prising a mutant of Par-4 selected from the group consisting
of 1-204, 137-221, 137-213, 137-198 and 137-195. The

50

invention also contemplates a recombinant DNA vector com
prising one or more of these sequences operably linked to a

sion are often actively pursued by researchers and physicians.
Especially dif?cult to treat are those cancers Which are

hormonally related. These cancers include prostate cancer
and breast cancer.

of a unique domain of Par-4 (the SAC domain) Which can
cause apoptosis in previously resistant cancer cells, but not in

Prostate cancer is the most commonly diagnosed cancer in
men and the second leading cause of cancer-related deaths in
men in the United States. According to the American Cancer
Society, about 198,100 neW cases of prostate cancer Will be

transcription regulatory element. The invention further con
templates a cell comprising a DNA vector Wherein the cell is

preferably bacterial, fungal, plant, insect or mammalian. The

diagnosed in the United States in 2001, and about 31,500 men
Will die of the disease. See WWW.cancer.org/docroot/STT/
SHi0i2001.
Prostate cancer cells fall into tWo types: androgen depen
dent and androgen independent. Current treatment for pros

55

tate cancer involves hormone treatments that remove test

60

invention further contemplates an isolated polypeptide com

prising at least ?ve amino acid residues, Wherein the polypep
tide has a sequence encoded by a nucleic acid contained in
one or more sequences.

Another object of the present invention provides a method
of producing a polypeptide, comprising incubating a host cell

osterone, thereby killing the prostate cancer cells that are

comprising a nucleic acid encoding a polypeptide under con

dependent on the hormone. HoWever, androgen independent

ditions that permit expression of the polypeptide. The method
preferably comprises incubating a cell under conditions that

cancer cells, Which are the cells responsible for prostate can
cer spreading to other areas, are not killed by this treatment.

About 30 percent of patients develop androgen independent
prostate cancer Within three years of initial treatment, and
patients With androgen independent cancer have a poor pro g

65

permit expression of one or more polypeptides encoded by
the nucleic acid.
Another object of the present invention provides an anti
body that speci?cally binds to at least one immunogenic

US 7,786,275 B2
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component, wherein the immunogenic component is encoded

FIG. 2 shoWs that the NLS2 is required for nuclear entry,
inhibition of NF-B activity and induction of apoptosis. A

by one or more sequences of a Par-4 mutant.

Another object of the present invention provides a method

schematic representation of full length Par-4, NLS1 and

of screening for therapeutic agents comprising selecting a

NLS2 is shoWn in panel A. PC-3 cells Were transiently trans
fected With vector control, Par-4, NLS 1 or NLS2 or their

Par-4-associated speci?c sequence as a target sequence; con

GFP-tagged derivatives. The expression of endogenous Par-4
(control), and ectopic Par-4, NLS1 and NLS2 proteins Were
examined by Western blot analysis (B). Intracellular localiZa

tacting a test compound With the target sequence; and select
ing as candidate therapeutic agents those test compounds
Which bind to the target sequence.
The sequence is preferably a polypeptide encoded by a
Par-4 mutant. The invention further contemplates a therapeu

tion of NLS 1 and NLS2 (C), and their ability to induce
apoptosis (E), Were examined as indicated in the description
of FIG. 1. The apoptotic morphology of the NLS1 transfected
cell inpanel CTo determines the inhibition of NF-B transcrip
tional activity by Par-4 or its mutants (D). Cells Were trans
fected for 48 hours With a Re1A reporter system and -galac
tosidase plasmid together With vector, Par-4 or mutant
constructs. Lysates Were subjected to luciferase assays, and
luciferase activity Was normaliZed to the corresponding

tic compound comprising an agent Which binds to one or
more sequences of Par-4 mutant or a polypeptide encoded

thereby.
Another object of the present invention provides a kit for
detecting the presence of a Par-4 mutant-associated nucleic
acid in a sample comprising at least one container means
having disposed therein at least a ?rst nucleic acid molecule
of a Par-4 mutant. Preferably, at least one of the ?rst and
second nucleic acid molecule includes a detectable label.

Another object of the present invention provides a kit for
detecting the presence a Par-4 mutant-associated polypeptide
in a sample comprising at least one container means having
disposed therein a ?rst antibody speci?c for at least one
polypeptide of a Par-4 mutant. The kit preferably comprises a
second antibody speci?c for at least one polypeptide of a
Par-4 mutant. The kit preferably further comprises a means
for detecting at least one of the ?rst and second antibodies.

Another object of the present invention provides a method
of treating cancer in a subject suffering therefrom, compris
ing administering to the subject a Par-4 mutant, Wherein the

galactosidase activity. Inhibition of luciferase activity by
Par-4 or its mutants is expressed relative to the activity noted
20

With vector.

25

FIG. 3 shoWs that the leucine Zipper domain is not essential
for apoptosis. PC-3 cells Were transiently transfected With
untagged or GFP-tagged derivatives of various C-terminal
deletion mutants of Par-4 (A). After 48 hours, the cells Were
examined for intracellular localiZation of the mutants (B),

expression of the mutant proteins by Western blot analysis
(C), inhibition of NF-B transcriptional activity (D), and apo
30

administration of the Par-4 mutant causes reduction of tumors

resistant to Par-4. The types of cancer treated include, but are
not limited to, prostate cancer, breast cancer and lung cancer,
and head and neck tumors. The subject is preferably a canine,
a feline, an ovine, a primate, an equine, a porcine, a caprine,

Was visualized by confocal microscopy.
FIG. 4 shoWs the identi?cation of the core domain of Par-4
35

a camelid, an avian, a bovine, amphibian, ?sh or a murine

organism. The subject is preferably a primate. The primate is
preferably human. The Par-4 mutant is preferably 1-204,
137-221, 137-213, 137-198 and 137-195.
Another object of the present invention provides a pharma
ceutical composition for the treatment of cancer, comprising

40

an isolated and puri?ed Par-4 mutant and a pharmaceutically

therapy, chemotherapy or ioniZing radiation.

Which is su?icient for apoptosis. Cells Were transiently trans
fected With GFP-tagged derivatives of Par-4 deletion mutant
137-332 or 148-332 (A) and examined for intracellular local
iZation (B). Cells Were transiently transfected With various
deletion mutants ofPar-4 137-204, 137-195, 137-190 or their

GFP-tagged derivatives (C), and examined for expression by
Western blot analysis (D), intracellular localiZation (E), inhi
bition of NF-B activity (P), and apoptosis induction in the
presence or absence of ectopic dnFADD (G), as seen in FIG.
1.
FIG. 5 shoWs that the core domain of Par-4 has an expanded

acceptable diluent, carrier or excipient.
The mode of expression of the mutants in the cancer cells
may include, but not limited to, the use of adenoviral vectors
that can be injected intratumorally or intravenously, or as
peptides or as fusion With other proteins or With antibodies.
The use of these mutants can be combined With other forms of
cancer treatment including, but not limited to, hormone

ptosis (E), as seen in FIG. 1. To examine Fas translocation (F),
PC-3 cells Were transiently transfected With untagged C-ter
minal deletion mutants, and after 48 hours they Were stained
With anti-Fas antibody. Alexa Fluor 488 green ?uorescence

45

but cancer-speci?c apoptotic ability. Various cell lines Were
transiently transfected With GFP vector, GFP-Par-4 or GFP

137-195, and examined for apoptosis in androgen-dependent
or -independent prostate cancer cells or primary cells (A).
LNCaP cells Were transiently transfected With GFP vector or
50

GFP-137-195, With or Without dnFADD, and examined for
apoptosis induction (B), as seen in FIG. 1.

BRIEF DESCRIPTION OF THE DRAWINGS
DETAILED DESCRIPTION OF THE INVENTION

FIG. 1 shoWs the nuclear localiZation of Par-4 correlates
With apoptosis induction. Cells Were transfected With GFP

55

A. De?nitions

60

consistently With the manner in Which those terms are under
stood in the art.
By “androgen-independent” is meant cancer cells or

Par-4 and treated With propidium iodide (PI) to detect nuclei.
In general, the terms in the present application are used

Intracellular localiZation of GFP-Par-4 Was recorded by con

focal microscopy (A). GFP-Par-4 images are shoWn in the left
panel, and the overlay of the GFP-Par-4 and PI images are

shoWn in right panel. The yelloW color, resulting from the
co-localiZation of GFP green ?uorescence With reddish-or

tumors Which do not require androgen to progress and/or

ange PI staining (right panel), indicates the nuclear expres
sion of Par-4. To determine percentage of apoptosis, cells

proliferate.
By “expression vector” is meant a DNA construct contain
ing a DNA sequence Which is operably linked to a suitable

Were transfected With GFP-Par-4 or GFP-vector as the con

trol, and then subjected to DAPI staining. Apoptotic cells

65

control sequence capable of effecting the expression of said

Were quanti?ed and expressed as a percentage of the total

DNA in a suitable host. Such control sequences include a

number of transfected cells (B).

promoter to effect transcription, an optional operator

US 7,786,275 B2
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sequence to control such transcription, a sequence encoding

a unique core domain of Par-4 Which is required for the
induction of apoptosis has been discovered. This core domain
induces apoptosis in cancer cells, but not in normal cells.

suitable mRNA ribosome binding sites, and sequences Which
control termination of transcription and translation. The vec
tor may be a plasmid, a phage particle, or simply a potential
genomic insert. Once transformed into a suitable host, the

The inventors have discovered the folloWing important
mutants of Par-4. In summary, the folloWing mutants have
been unexpectedly found to induce apoptosis in cancer cells
Which are sensitive or resistant to full-length Par-4 (SEQ ID
NO: 1), but do not induce apoptosis in normal cells. They are

vector may replicate and function independently of the host
genome, or may, in some instances, integrate into the genome
itself. The invention is intended to include such other forms of
expression vectors Which serve equivalent functions and
Which are, or become, knoWn in the art.

1-204, 137-221, 137-213, 137-198 and 137-195 of SEQ ID
NO: 1. One advantage of these mutants is that they de?ne the
active domain of Par-4 and localiZe that active domain to the
59 amino acid region betWeen amino acid 137 and 195 of
Par-4 (the Wild type Par-4 has 332 amino acids, SEQ ID NO:
1). This 59 amino acid region contains a nuclear localiZation
sequence that alloWs entry of the protein into the nucleus and
tWo phosphorylation sites. Thus, these mutants are useful in
inducing apoptosis in cancer cells.

Host cells are transformed or transfected With vectors con

structed using recombinant DNA techniques. Such trans
formed host cells are capable of either replicating vectors
encoding the carbonyl hydrolase mutants or expressing the
desired carbonyl hydrolase mutant. In the case of vectors
Which encode the pre or prepro form of the carbonyl hydro
lase mutant, such mutants, When expressed, are typically
secreted from the host cell into the host cell medium.

III. Par-4 Mechanism of Action

By “operably linked” is meant the relationship betWeen
tWo DNA regions such that they are functionally related to
each other. For example, a presequence is operably linked to
a peptide if it functions as a signal sequence, participating in
the secretion of the mature form of the protein most probably

20

The Par-4 gene, ?rst identi?ed by the inventors (see Sells et

al., 1994) in prostate cancer cells undergoing apoptosis,

scription of the sequence; a ribosome binding site is operably

encodes a proapoptotic protein that is remarkably effective in
inducing cancer cell apopto sis and tumor regression in animal
models. The inventors have found that Par-4 induces apopto
sis in androgen independent prostate cancer cells, such as

linked to a coding sequence if it is positioned so as to permit
translation.

HoWever, Par-4 does not induce apoptosis in androgen depen

involving cleavage of the signal sequence. A promoter is
operably linked to a coding sequence if it controls the tran

The genes encoding the naturally-occurring Par-4 may be
obtained in accord With the general methods described by

25

PC3 and DU145, and in Ras transformed mouse ?broblasts.

dent prostate cancer cells, such as LNCaP, in immortalized
30

methods knoWn in the art.
The cloned Par-4 may then be used to transfect a host cell
in order to express the Par-4. The Par-4 gene may then be

range of apoptotic insults, including chemotherapeutic

ligated into a high copy number plasmid. This plasmid repli
cates in hosts in the sense that it contains the Well-knoWn

35

elements necessary for plasmid replication; a promoter oper
ably linked to the gene in question (Which may be supplied as
the gene’s oWn homologous promoter if it is recognized, i.e.,

transcribed, by the host), a transcription termination and
polyadenylation region (necessary for stability of the mRNA

cells or in primary cultures of normal prostate epithelial and
stromal cells.
Overexpression of Par-4 in cells that are resistant to direct
apoptosis by Par-4 renders the cells supersensitive to a broad
agents, TNF, or ioniZing radiation. The Par-4 gene maps to
human chromosome 12q21, Which is often deleted in pancre
atic cancer. Par-4 expression is doWnregulated in renal cell
carcinoma relative to the normal proximal tubular cell com
partment. Moreover, oncogenes such as Ras, Raf or Src

40

doWnregulate Par-4 expression, and restoration of Par-4 level

transcribed by the host from the Par-4 gene in certain eucary
otic host cells) Which is exogenous or is supplied by the

results in inhibition of oncogene induced transformation of

endogenous terminator region of the Par-4 gene and, desir

an antisense oligodeoxynucleotide has been found to protect
neuronal cells from apoptosis in cell culture and animal mod

cells. Inhibition of Par-4 With a dominant negative mutant or

ably, a selection gene such as an antibiotic resistance gene

that enables continuous cultural maintenance of plasmid

45

els of neurodegenerative diseases.
The transcription activity of NFkB is an essential anti
apoptotic target of Par-4. NfkB plays a crucial role in in?am
mation and immune response by activating the transcription
of a number of key cytokines and cytokine receptors, antago

50

niZing apoptosis by upregulation of inhibitor of apoptosis
proteins and supporting cell proliferation. More importantly,

infected host cells by groWth in antibiotic-containing media.
High copy number plasmids also contain an origin of repli
cation for the host, thereby enabling large numbers of plas
mids to be generated in the cytoplasm Without chromosomal
limitations. HoWever, it is Within the scope herein to integrate
multiple copies of the Par-4 gene into host genome. This is

NFkB plays an essential role in oncogenesis and in the resis
tance of tumor cells to ioniZing radiation and chemotherapy.
The transcription potential of NFkB, a heterodimer betWeen

facilitated by procaryotic and eucaryotic organisms Which are
particularly susceptible to homologous recombination.
II. Introduction

55

The inventors have discovered that various in vitro muta
tions involving the deletion of one or more amino acids Within
a Par-4 amino acid sequence can confer advantageous prop

erties to such mutants especially With regard to inducing

scription activity in androgen independent prostate cancer
60

cancer cell death.

Speci?cally, the Par-4 gene has been mutated by modifying

Par-4 correlates With susceptibility to apoptosis. Speci?cally,

cell lines.
Previous studies indicated that the inhibitory effect of Par-4

is targeted toWard the transactivation domain (TA1) of the
RelA subunit of NFkB. Inhibition of NFkB activity by super

the DNA to encode the substitution of one or more amino

acids at various amino acid residues Within the mature form of
the Par-4 molecule.
The inventors have discovered that nuclear translocation of

subunits p65 (RelA) and p50, is fully activated by transloca
tion to the nucleus and phosphorylation of RelA. Par-4 inhib
its Ras or Raf induced NFkB transcriptional activity in mouse
?broblast cells and the constitutively activated NFkB tran

repressor IkBa is suf?cient to induce apoptosis in NIH 3T3
65

cells expressing oncogenic Ras. Overexpression of Par-4 is
suf?cient to induce apoptosis in these cells. HoWever, in

androgen independent prostate cancer cells, inhibition of

US 7,786,275 B2
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NFkB is not suf?cient to induce apoptosis or to cause tumor

identifying key differences between cancer and normal cells,

regression, suggesting that Par-4 may also activate a prodeath
pathway in these cells.
Par-4 was found to induce apoptosis by coparallel activa

and for molecular therapy of cancer.
Thus, the present invention indicates that Par-4 transloca
tion into the nucleus is essential for induction of apoptosis.
The NLS2 domain of Par-4 is essential for nuclear transloca
tion, and resistance to apoptosis was noted in cells that did not

tion of the FasL/Fas pathway and inhibition of NFkB tran

scription activity in the androgen independent cells. Fas
(CD95) is a member of the TNFR family of death receptors
that is activated by binding to FasL leading to the formation of
DISC. This complex is composed of the trimerized Fas,

translocate Par-4 to the nucleus or with Par-4 constructs that

lacked an intact NLS2 domain. Moreover, nuclear transloca

FADD and procaspase 8 and its formation leads to the acti
vation of caspase8 and to the induction of downstream

tion was essential for inhibition of RelA transcription activity
by Par-4. Because inhibition of RelA activity is critical for

caspases and apoptosis. Speci?cally, Par-4 activates the Fas
pathway by promoting the Fas/FasL translocation to the cell
membrane and by protecting the Fas apoptotic pathway from
the inhibitory effects of zPKC. Activation of the Fas pathway

apoptosis by Par-4, these observations suggest that Par-4 has
a nuclear function that includes RelA transcription inhibition

and induction of apoptosis. Further, the deletion analysis
identi?ed the 59 amino acid core domain of Par-4 that con

and inhibition of NFkB activity are both essential for apop

stitutes a minimal region of Par-4 which is suf?cient for
apoptosis. This core domain translocates into the nucleus in
both cancer and normal or immortalized cells, but is selective

tosis induction by Par-4 in androgen independent prostate
cancer cells.

Despite the advances made in understanding the mecha
nism of action of Par-4, the active domains of Par-4, as well as
its functional localization, were largely unknown. The amino

20

acid sequence of the Par-4 protein predicts a leucine zipper
domain at its C-terminal end, between amino acids 292 and
332. This domain is involved in binding to all currently

known partners of Par-4, including WT1, zPKC, p62 and Dlk.

Because this domain does not induce apoptosis in normal
cells but induces apoptosis in diverse cancer cells, it has been
25

The leucine zipper domain is required for sensitization to
apoptosis by Par-4. A deletion mutant of Par-4 lacking the
leucine zipper domain (DZip) is unable to sensitize cells to
apoptotic stimuli. Moreover, PC12 cells expressing DZip are
insensitive to Ab142 or withdrawal of trophic factors. These

in inducing apoptosis of the cancer cells, regardless of
whether or not they are sensitive to wild type Par-4. This core
domain is 100% conserved in rat, mouse and human Par-4.

30

designated Selective Apoptosis induction of Cancer cells
(i.e., SAC domain). This domain does not resemble the death
domains (DD) or death effector domains (DED) of other

proapoptotic proteins. Unlike the previously characterized
DD/DED, the SAC domain speci?cally induces apoptosis in

?ndings indicate that the C-terminal leucine zipper domain is

cancer cells and not normal cells. Because Par-4 causes

indispensable for the apoptosis sensitizing function of Par-4
(see Sells et al. 1997).

remarkable regression of solid tumors by apoptosis driven by
Fas pro-death pathway activation and inhibition of NFkB

Par-4 contains two putative nuclear localization sequences,
NLS1 at amino acids 20 to 25 and NLS2 at amino acids
137-153, both in the N terminal half of Par-4. In most tissues

activity, the SAC domain, which utilizes a similar mechanism
35

and cell types, endogenous Par-4 is localized in the cyto
plasm. Par-4 is cytoplasmic in the immortalized ?broblast

of cancer.

cells NIH 3T3, and deletion of the ?rst 68 amino acids includ

ing NLS1 does not affect the apoptosis sensitizing function of

40

The leucine zipper domain of Par-4 is necessary for apop
tosis sensitization of cells to diverse apoptotic insults (see

45

Sells et al., 1997). This sensitizing action is regulated by Par-4
interaction via its leucine zipper domain, with WT1, DLK,
zPKC, and p62. Depending on the partner and the cellular
context, the apoptosis sensitizing function of Par-4 is imple
mented in the cytoplasm when regulated by DLK, zPKC, and
p62, or in the nucleus when regulated by WT1. The ?ndings
of the present invention suggest that the leucine zipper

Par-4. The following observations support a nuclear function
for Par-4: (1) the presence of a bipartite nuclear localization
sequence (NLS2); (2) the ability of Par-4 to inhibit RelA

transcription activity; (3) direct binding to the nuclear pro
teins Dlk and WT1; and (4) binding to WT1 and inhibition of
the bcl2 promoter.
Recent studies indicate that the leucine zipper domain pro
tein Par-4 induces apoptosis in certain cancer cells by activa

tion of the Fas prodeath receptor pathway and coparallel
inhibition of the cell survival NFkB transcription activity.

50

However, the intracellular localization or functional domains

of Par-4 involved in apoptosis remained unknown.
In the present invention, structure function analysis indi
cated that inhibition of NFkB transcription activity and apo
ptosis are dependent on Par-4 translocation to the nucleus via
a bipartite nuclear localization signal sequence NLS2. Cancer
cells that were resistant to Par-4 induced apoptosis retained
Par-4 in the cytoplasm. A 59 amino acid core from amino
acids 137 to 195 that included NLS2, but not the C-terminal
leucine zipper domain of Par-4, was necessary and su?icient

of apoptosis, also causes tumor regression by apoptosis. The
cancer speci?c apoptotic potential of the SAC domain renders
it a promising candidate for directed molecular therapeutics

55

domain of Par-4 is not essential for apoptosis induced by
Par-4 acting alone. Thus, the interactive partners identi?ed
thus far might not be involved in regulation of the direct
apoptotic action of Par-4, unless they also bind to the core
domain. In addition, the deletion of the leucine zipper domain
resulted in increased nuclear translocation of Par-4. Because
the leucine zipper domain contains a putative nuclear exclu

sion sequence (amino acids 291 to 302) that may compete
with NLS2 sequence, it is believed that the distribution of
Par-4 in the nuclear versus cytoplasmic compartments may be
60

to induce Fas pathway activation, inhibition of nuclear NFkB

regulated by the relative activities of the NES and NLS2
domains.

transcription activity and apoptosis. Most importantly, this

In summary, by deletion analysis, the present invention

core domain of Par-4 had an expanded apoptotic target range
extending to the cancer cells that were resistant to Par-4, but
not to normal cells. These ?ndings have identi?ed a unique
‘death domain’ that is selective for apoptosis induction in

provides a unique core domain of Par-4 that is essential for

cancer cells, (i.e., the SAC domain), which holds promise for

65

nuclear entry, Fas pro-death pathway activation, inhibition of
NFkB activity and induction of apoptosis. This domain
extends the susceptibility spectrum of Par-4 to diverse cancer
cells, regardless of whether they are susceptible or resistant to

US 7,786,275 B2
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Par-4. Because this domain shows selective action against

exists in cells or in a mixture of nucleic acids such as a

cancer cells but not normal cells, it has both academic and

library), and may have undergone further processing. “Iso

therapeutic applications.

lated”, as used herein, refers to nucleic or amino acid

sequences that are at least 60% free, preferably 75% free, and
most preferably 90% free from other components with which
they are naturally associated. “Isolated” nucleic acids (poly

IV. Mutants of Par-4

The inventors have discovered the following important

nucleotides) include nucleic acids obtained by methods

mutants of Par-4. In summary, the following mutants have
been unexpectedly found to induce apoptosis in cancer cells
which are sensitive or resistant to full-length Par-4, but do not

described herein, similar methods or other suitable methods,

including essentially pure nucleic acids, nucleic acids pro

duced by chemical synthesis, by combinations of biological

induce apoptosis in normal cells. They are 1-204, 137-221,
137-213, 137-198 and 137-195. One advantage of these
mutants is that they de?ne the active domain of Par-4 and
localize that active domain to the 59 amino acid region
between amino acid 137 and 195 of Par-4 (the wild type Par-4
has 332 amino acids). This 59 amino acid region contains a
nuclear localization sequence that allows entry of the protein
into the nucleus and two phosphorylatron sites. Thus, these
mutants are useful in inducing apoptosis in cancer cells.
Those of ordinary skill in the art will recognize that the

and chemical methods, and recombinant nucleic acids which
are isolated. Nucleic acids referred to herein as “recombi

nant” are nucleic acids which have been produced by recom

binant DNA methodology, including those nucleic acids that
are generated by procedures which rely upon a method of
arti?cial recombination, such as the polymerase chain reac

tion (PCR) and/or cloning into a vector using restriction

20

particular methods of polymorphism identi?cation described
herein are not intended to be limiting of the present invention.

Any of the variety of other known techniques, such as, for

example, RNA-DNA hybrid cleavage using RNase A, mis
match detection using heteroduplex analysis, denaturing gra
dient electrophoresis, and chemical cleavage heteroduplex

lated nucleic acids which code for polypeptides having a
certain function can be identi?ed and isolated by methods
25

known in the art.
A further embodiment of the invention is antisense nucleic
acids or oligonucleotides which are complementary, in whole
or in part, to a target molecule comprising a sense strand, and
can hybridize with the target molecule. The target can be

30

DNA, or its RNA counterpart (i.e., wherein T residues of the
DNA are U residues in the RNA counterpart). When intro
duced into a cell, antisense nucleic acids or oligonucleotides
can inhibit the expression of the gene encoded by the sense

DNA (see, Current Protocols in Human Genetics, Volume 1,

Chapter 7, John Wiley and Sons, 1995).
As described above, the present invention relates to Par-4

sequences, RNA, fragments of the genomic, cDNA, or
nucleic acids comprising 5, 10, 15, 30, 60, 100, 200, 500 or
more contiguous nucleotides, and the complements thereof.
Closely related variants are also included as part of this inven
tion, as well as recombinant nucleic acids comprising at least

50, 60, 70, 80, or 90% of the nucleic acids described above
which would be identical to the Par-4 nucleic acids except for

enzymes. “Recombinant” nucleic acids are also those that
result from recombination events that occur through the natu
ral mechanisms of cells, but are selected for after the intro
duction to the cells of nucleic acids designed to allow or make
probable a desired recombination event. Portions of the iso

strand or the mRNA transcribed from the sense strand. Anti
35

sense nucleic acids can be produced by standard techniques
known in the art.
In a particular embodiment, an antisense nucleic acid or

one or a few substitutions, deletions, or additions.

Further, the nucleic acids of this invention include the

oligonucleotide is wholly or partially complementary to and

adjacent chromosomal regions of Par-4 required for accurate
expression of the respective gene. In a preferred embodiment,

can hybridize with a target nucleic acid (either DNA or RNA),
wherein the target nucleic acid can hybridize to a nucleic acid

the present invention is directed to at least 15 contiguous
nucleotides of the nucleic acid sequence of Par-4.
It is understood that, as a result of the degeneracy of the
genetic code, many nucleic acid sequences are possible which
encode a Par-4-like protein orpolypeptide. Some of these will
have little homology to the nucleotide sequences of any

40

having the sequence of the complement of the strand. For
example, an antisense nucleic acid or oligonucleotide can be

complementary to a target nucleic acid having the sequence
45

known or naturally-occurring Par-4-like gene but can be used

to produce the proteins and polypeptides of this invention by
selection of combinations of nucleotide triplets based on
codon choices. Such variants, while not hybridizable to a

50

shown as the strand of the open reading frame or nucleic acid
encoding a functional equivalent of Par-4, or to a portion of
these nucleic acids suf?cient to allow hybridization. A por
tion, for example, a sequence of 16 nucleotides could be
suf?cient to inhibit expression of the protein. Or, an antisense
nucleic acid or oligonucleotide complementary to 5' or 3'
untranslated regions, or overlapping the translation initiation

naturally occurring Par-4 gene, are contemplated within this

codon (5' untranslated and translated regions), of the Par-4

invention.
The nucleic acids described herein are used in the methods
of the present 30 invention for production of proteins or

gene, or a gene encoding a functional equivalent can also be

polypeptides, through incorporation into cells, tissues, or
organisms. In one embodiment, DNA containing all or part of
the coding sequence for a Par-4 polypeptide, or DNA which
hybridizes to DNA, is incorporated into a vector for expres
sion of the encoded polypeptide in suitable host cells. The
encoded polypeptide consisting of Par-4, or its functional
equivalent is capable of normal activity. The term “vector” as
used herein refers to a nucleic acid molecule capable of trans
porting another nucleic acid to which it has been linked. A
vector, for example, can be a plasmid.

55
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effective. In another embodiment, the antisense nucleic acid
is wholly or partially complementary to and can hybridize
with a target nucleic acid which encodes a Par-4 polypeptide.
In addition to the antisense nucleic acids of the invention,
oligonucleotides can be constructed which will bind to
duplex nucleic acid either in the gene or the DNA:RNA
complex of transcription, to form a stable triple helix-con
taining or triplex nucleic acid to inhibit transcription and/or
expression of a gene encoding Par-4, or its functional equiva
lent. Such oligonucleotides of the invention are constructed

using the base-pairing rules of triple helix formation and the
nucleotide sequence of the gene or mRNA for Par-4. These

Nucleic acids referred to herein as “isolated” are nucleic 65 oligonucleotides can block Par-4-type activity in a number of

acids separated away from the nucleic acids of the genomic

ways, including prevention of transcription of the Par-4 gene

DNA or cellular RNA of their source of origin (e.g., as it

or by binding to mRNA as it is transcribed by the gene.
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and polypeptides of this invention can be isolated and/or

under appropriate conditions or by adding the complemen
tary strand using DNA polymerase With an appropriate
primer sequence.

recombinant. Proteins or polypeptides referred to herein as
“isolated” are proteins or polypeptides puri?ed to a state

These nucleic acids can encode full-length variant forms of
proteins as Well as the naturally-occurring protein. The vari

beyond that in Which they exist in cells. In a preferred
embodiment, they are at least 10% pure; i.e., most preferably
they are substantially puri?ed to 80 or 90% purity. “Isolated”
proteins or polypeptides include proteins or polypeptides
obtained by methods described infra, similar methods or
other suitable methods, and include essentially pure proteins

ant proteins (Which could be especially useful for detection

The invention also relates to proteins or polypeptides

encoded by the nucleic acids described herein. The proteins

and treatment of disorders) Will have the variant amino acid

sequences encoded by polymorphisms, When said polymor
phisms are read so as to be in-frame With the full-length

coding sequence of Which it is a component.
Nucleic acid constructs prepared for introduction into a

orpolypeptides, proteins orpolypeptides produced by chemi

prokaryotic or eukaryotic host Will comprise a replication
system recognized by the ho st, including the intended nucleic
acid fragment encoding the selected protein or polypeptide,
and Will preferably also include transcription and transla
tional initiation regulatory sequences operably linked to the

cal synthesis or by combinations of biological and chemical
methods, and recombinant proteins or polypeptides Which are
isolated. Proteins or polypeptides referred to herein as

“recombinant” are proteins or polypeptides produced by the
expression of recombinant nucleic acids. In a preferred

protein encoding segment. Expression vectors may include,

embodiment, the protein or portion thereof has at least one
function characteristic of a Par-4 protein or polypeptide.
A “portion” as used herein With regard to a protein or

for example, an origin of replication or autonomously repli
cating sequence (ARS) and expression control sequences, a
promoter, an enhancer and necessary processing information

20

polypeptide, refers to fragments of that protein or polypep
tide. The fragments can range in size from 5 amino acid
residues to all but one residue of the entire protein sequence.
Thus, a portion or fragment can be at least 5, 5-50, 50-100,
100-200, 200-400, 400-800, or more 20 consecutive amino
acid residues of a Par-4 protein or polypeptide, for example,
Table 2, or a variant thereof. The invention also relates to

sites, such as ribosome-binding sites, RNA splice sites, poly
adenylation sites, transcriptional terminator sequences, and
25

the same or related species, Which alloW the protein to cross

and/or lodge in cell membranes, and thus attain its functional

isolated, synthesized and/or recombinant portions or frag

topology, or be secreted from the cell. Such vectors may be

prepared by means of standard recombinant techniques Well

ments of a Par-4 protein or polypeptide as described above.

Polypeptide fragments of the enzyme can be made Which

mRNA stabilizing sequences. Secretion signals are also
included, Where appropriate, Whether from a native Par-4
protein or from other receptors or from secreted proteins of

30

knoWn in the art and discussed, for example, in Sambrook et

al., Molecular Cloning. A Laboratory Manual, 2nd Ed. (Cold

have full or partial function on their oWn, or Which When

mixed together (though fully, partially, or nonfunctional

Spring Harbor Laboratory, Cold Spring Harbor, NY. (1989)

alone), spontaneously assemble With one or more other

or Ausubel et al., Current Protocols in Molecular Biology, J.

polypeptides to reconstitute a functional protein having at
least one functional characteristic of a Par-4 protein of this
invention.
The invention also concerns the use of the nucleotide

Wiley and Sons, NY (1992).
35

and Will include, When appropriate, those naturally associated
With Par-4 genes. Examples of Workable combinations of cell
lines and expression vectors are described in Sambrook et al.,

sequence of the nucleic 30 acids of this invention to identify

DNA probes for Par-4 genes, PCR primers to amplify Par-4
genes, and regulatory elements of the Par-4 genes.
The nucleic acids of this invention can be produced in large
quantities by replication in a suitable host cell. Natural or
synthetic nucleic acid fragments, comprising at least ten con
tiguous bases coding for a desired peptide or polypeptide can
be incorporated into recombinant nucleic acid constructs,

40

Molecular Cloning A Laboratory Manual, 2nd Ed. (Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY. (1989)
or Ausubel et al., Current Protocols in Molecular Biology, J.

Wiley and Sons, NY (1992). Many useful vectors are knoWn
in the art and can be obtained from such vendors as Stratagene
45

usually DNA constructs, capable of introduction into and
replication in a prokaryotic or eukaryotic cell. Usually the
nucleic acid constructs Will be suitable for replication in a
unicellular host, such as yeast or bacteria, but may also be

intended for introduction to (With and Without integration

An appropriate promoter and other necessary vector
sequences Will be selected 15 so as to be functional in the host,

50

Within the genome) cultured mammalian or plant or other

(supra), NeW England BioLabs, Beverly, Mass., USA,
Promega Biotech, and otherbiotechnology product suppliers.
Promoters such as the trp, lac and phage promoters, tRNA
promoters and glycolytic enzyme promoters may be used in
prokaryotic hosts. Useful yeast promoters include promoter
regions for metallothionein, 3-phosphoglycerate kinase or
other glycolytic enzymes such as enolase or glyceraldehyde

eukaryotic cells, cell lines, tissues, or organisms. The puri?

3-phosphate dehydrogenase, enzymes responsible for mal

cation of nucleic acids produced by the methods of the present
invention is described, for example, in Sambrook et al,

tose and galactose utilization, and others. In addition, the

Molecular Cloning. A Laboratory Manual, 2nd Ed. (Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY (1989)

construct may be joined to an ampli?able gene so that mul
55

tiple copies of the gene may be made. For appropriate

60

Enhancers and Eukaryotic Gene Expression, Cold Spring
Harbor Press, Cold Spring Harbor, NY (1983). While such
expression vectors may replicate autonomously, they may
also replicate by being inserted into the genome of the host

enhancer and other expression control sequences, see also

or Ausubel et al, Current Protocols in Molecular Biology, J.

Wiley and Sons, NY (1992).
The nucleic acids of the present invention can also be

produced by chemical synthesis, e. g., by the pho sphoramidite
method described by Beaucage et al., Tetra. Letts., 22:1859

cell, by methods Well knoWn in the art.
Expression and cloning vectors Will likely contain a select
able marker, a gene encoding a protein necessary for survival

1862 (1981) or the triester method according to Matteucci et

al., .1. Am. Chem. Soc, 103:3 185 (1981), and can performed
on commercial, automated oligonucleotide synthesizers. A
double-stranded fragment may be obtained from the single

stranded product of chemical synthesis either by synthesizing
the complementary strand and annealing the strands together

or groWth of a host cell transformed With the vector. The
65

presence of this gene ensures groWth of only those host cells
Which express the inserts. Typical selection genes encode
proteins that a) confer resistance to antibiotics or other toxic
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substances, e.g. ampicillin, neomycin, methotrexate, b)

sequences and proteins in other species. These Par-4 gene
sequences and proteins are used in the diagnostic/prognostic,

complement auxotrophic de?ciencies, or c) supply critical
nutrients not available from complex media, e.g., the gene
encoding D-alanine racemase for Bacilli. The choice of the
proper selectable marker Will depend on the host cell, and
appropriate markers for different hosts are Well knoWn in the

therapeutic and drug screening methods described herein for
the species from Which they have been isolated.
Expression and puri?cation of the Par-4 proteins of the

art.

facilitate the cloning, expression and puri?cation of mem

invention can be performed essentially as outlined beloW. To

The vectors containing the nucleic acids of interest can be

brane and secreted protein a gene expression system, such as

transcribed in vitro, and the resulting RNA introduced into the

the pET System (Novagen), for cloning and expression of

host cell by Well-knoWn methods, e.g., by injection (see,

recombinant proteins in E. coli is selected. Also, a DNA
sequence encoding a peptide tag, the His-Tap, is fused to the
3' end of DNA sequences of interest to facilitate puri?cation
of the recombinant protein products. The 3 end is selected for
fusion to avoid alteration of any 5' terminal signal sequence.
Nucleic acids chosen, for example, from the nucleic acids
set forth in Table 2 for cloning the genes are prepared by

Kubo et al., FEBS Letts. 241:119 (1988)), or the vectors can

be introduced directly into host cells by methods Well knoWn
in the art, Which vary depending on the type of cellular host,

including electroporation; transfection employing calcium
chloride, rubidium chloride, calcium phosphate, DEAE-dex
tran, or other sub stances; microproj ectile bombardment; lipo
fection; infection (Where the vector is an infectious agent,
such as a retroviral genome); and other methods. See, Sam
brook et al., 1989 and Ausubel et al., 1992. The introduction
of the nucleic acids into the host cell by any method knoWn in

polymerase chain reaction (PeR). Synthetic oligonucleotide
primers speci?c for the 5 and 3 ends of the nucleotide
sequences are designed and purchased from Life Technolo
20

the art, including those described above, Will be referred to
herein as “transformation.” The cells into Which have been
introduced nucleic acids described above are meant to also
include the progeny of such cells.

Large quantities of the nucleic acids and proteins of the
present invention may be prepared by expressing the Par-4

25

nucleic acids or portions thereof in vectors or other expres

gies (Gaithersburg, Md.). All forWard primers (speci?c for the
5' end of the sequence) are designed to include an Ncol
cloning site at the 5' terminus. These primers are designed to
permit initiation of protein translation at the methionine resi
due encoded Within the Ncol site folloWed by a valine residue
and the protein encoded by the DNA sequence. All reverse
primers (speci?c for the 3' end of the sequence) include an
EcoRI site at the 5' terminus to permit cloning of the sequence

sion vehicles in compatible prokaryotic or eukaryotic host

into the reading frame of the pET-28b. The pET-28b vector

cells. The most commonly used prokaryotic hosts are strains
of Escherichia coli, although other prokaryotes, such as

provides a sequence encoding an additional 20 carboxyl
terminal amino acids including six histidine residues (at the

30

Bacillus subtilis or Pseudomonas may also be used.

C-terminus), Which comprise the histidine a?inity tag.

Mammalian or other eukaryotic host cells, such as those of
yeast, ?lamentous fungi, plant, insect, or amphibian or avian

Genomic DNA prepared from an individual as described in
Example 1 is used as the source of template DNA for PCR

species, may also be useful for production of the proteins of
the present invention. Propagation of mammalian cells in
culture is per se Well known. See, Jakoby and Pastan (eds.),
Cell Culture. Methods in Enzymology, volume 58, Academic

35

ampli?cation (Ausubel et al., CurrentProtocols in Molecular
Biology, John Wilty & Sons (1994)). To amplify a DNA
sequence containing the nucleotide sequence, genomic DNA
(50 ng) is introduced into a reaction vial containing 2 mM

Press, Inc., Harcourt Brace Jovanovich, N.Y., (1979)).

MgCl2, 1 micromolar synthetic oligonucleotide primers (for

Examples of commonly used mammalian host cell lines are
VERO and HeLa cells, Chinese hamster ovary (CHO) cells,

Ward and reverse primers) complementary to and ?anking a
de?ned Par-4 region, 0.2 mM of each of deoxynucleotide

40

triphosphate, dATP, dGTP, dCTP, dTTP and 2.5 units of heat
stable DNA polymerase (Amplitaq, Roche Molecular Sys
tems, lnc., Branchburg, NJ.) in a ?nal volume of 100 micro

and W138, BHK, and CQS cell lines, although it Will be
appreciated by the skilled practitioner that other cell lines
may be appropriate, e.g., to provide higher expression desir
able glycosylation patterns, or other features.
Clones are selected by using markers depending on the

liters.

mode of the vector construction. The marker may be on the
same or a different DNA molecule, preferably the same DNA

Upon completion of thermal cycling reactions, each
sample of ampli?ed DNA is puri?ed using the Qiaquick Spin
PCR puri?cation kit (Qiagen, Gaithersburg, Md.). All ampli

molecule. In prokaryotic hosts, the transformant may be
selected, e.g., by resistance to ampicillin, tetracycline or other

?ed DNA samples are subjected to digestion With the restric
tion endonucleases, e.g., Ncol and EcoRI (NeW England

antibiotics. Production of a particular product based on tem
perature sensitivity may also serve as an appropriate marker.

45
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Prokaryotic or eukaryotic cells transformed With the
nucleic acids of the present invention Will be useful not only
for the production of the nucleic acids and proteins of the

present invention, but also, for example, in studying the char
acteristics of Par-4 proteins.
Antisense nucleic acid sequences are useful in preventing
or diminishing the expression of Par-4 genes, as Will be appre
ciated by one skilled in the art. For example, nucleic acid
vectors containing all or a fragment of Par-4 genes, comple

55

The probes and primers based on the Par-4 gene sequences
disclosed herein are used to identify homologous Par-4 gene

rose gels. DNA is visualiZed by exposure to ethidium bromide
and long Wave UV irradiation. DNA contained in slices iso
lated from the agarose gel are puri?ed using the Bio 101

GeneClean Kit protocol (Bio 101,V1sta, Calif.).
The pET-28b vector is prepared for cloning by digestion
With restriction endonucleases, e.g., Ncol and EcoRI (NeW
60

England BioLabs, Beverly, Mass.) (Ausubel et al., Current
Protocols in Molecular Biology, John Wiley & Sons, Inc.
(1994)). The pET-28a vector, Which encodes the histidine

mentary sequences of the former may be placed under the
control of a promoter in an antisense orientation and intro
duced into a cell. Expression of such an antisense construct
Within a cell Will interfere With Par-4 transcription and/or
translation and/ or replication.

BioLabs, Beverly, Mass., USA.) (Ausubel et al., Current
Protocols in Molecular Biology, John Wiley & Sons, Inc.
(1994)). DNA samples are then subjected to electrophoresis
on 1.0% NuSeive (IFMC BioProducts, Rockland, Me.) aga

a?inity tag that can be fused to the 5 end of an inserted gene,

is prepared by digestion With appropriate restriction endonu
65

cleases.
Following digestion, DNA inserts are cloned (Ausubel et

al., Current Protocols in Molecular Biology, John Wiley &
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Sons, Inc. (1994)) into the previously digested pET-28b

Biochem., 157:169-180 (1986)). Protein concentrations are

expression vector. Products of the ligation reaction are then
used to transform the BL21 strain of E. coil (Ausubel et al.,

also measured by the method of Bradford, Anal. Biochem.,
72:248-254 (1976) and LoWry et al., J. Biol. Chem., 193:265

CurrentProtocols in MolecularBiology, John Wiley & Sons,

275 (1951) using bovine serum albumin as a standard.

Inc. (1994)) as described beloW.
Competent bacteria, E. coli strain BL21 or E. coli strain
BL21 (DE3), are transformed With recombinant pET expres

purchased from BioRad (Hercules, Calif.), and stained With

sionplasmids carrying the cloned sequence according to stan
dard methods (Ausubel et al., CurrentProtocols in Molecular

bit skeletal muscle myosin (200 kDa), E. coli-galactosidase
(1 16 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine

SDS-polyacrylamide gels of various concentrations are
Coomassie blue. Molecular Weight markers may include rab

Biology, John Wiley & Sons, Inc. (1994)). Brie?y, 1 micro

serum albumin (66.2 kDa), ovalbumin (45 kDa), bovine car

liter of ligation reaction is mixed With 50 microliters of elec

bonic anyhdrase (31 kDa), soybean trypsin inhibitor (21.5

trocompetent cells and subjected to a high voltage pulse, after

kDa), egg White lysoZyme (14.4 kDa) and bovine aprotinin

Which samples Were incubated in 0.45 ml SOC medium

(6.5 kDa). Proteins can also be isolated by other conventional
means of protein biochemistry and puri?cation to obtain a

(0.5% yeast extract, 2.0% tryptone, 10 mM NaCl, 2.5 mM
KC1, 10 mM MgC12, 10 mM MgSO4 and 20 mM glucose) at

5

37° C. With shaking for 1 hour. Samples are then spread on LB

agar plates containing 25 g/ml kanamycin sulfate for groWth
overnight. Transformed colonies of BL21 are then picked and
analyZed to evaluate cloned inserts, as described beloW.
The pET vector can be propagated in any E. coil K-12

Enzymology, Vol. 104, Academic Press, NeW York (1984);
Scoopes, Protein Puri?cation, Principles and Practice, 2'”
Ed., Springer-Verlag, NeW York (1987); and Deutscher (ed.),
20

strain, e.g., HNIS 174, HB101, JM109, DH5 and thelike, for
purposes of cloning or plasmid preparation. Hosts for expres
sion include E. coil strains containing a chromosomal copy of
the gene for T7 RNA polymerase. These hosts are lysogens of
bacteriophage DE3, a lambda derivative that carries the lad
gene, the lacUV5 promoter and the gene for T7 RNA poly
merase. T7 RNA polymerase is induced by addition of iso

25
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To express the recombinant sequence, 50 ng of plasmid
DNA are isolated as described above to transform competent
35

for the Par-4 recombinant constructions. Transformed cells
Were cultured in SOC medium for 1 hour, and the culture is

then plated on LB plates containing 25 ug/ml kanamycin

40

sulfate. The folloWing day, the bacterial colonies are pooled
and groWn in LB medium containing kanamycin sulfate (25
ug/ml) to an optical density at 600 nM of 0.5 to 1.0 0D. units,
at Which point 1 mM IPTG Was added to the culture for 3
hours to induce 30 gene expression of the Par-4 recombinant
DNA constructions.
After induction of gene expression With IPTG, bacteria are
collected by centrifugation in a Sorvall RC-3B centrifuge at
3500><g for 15 minutes at 4° C. Pellets are resuspended in 50
ml of cold mM Tris-HC1, pH 8.0, 0.1 M NaCl and 0.1 mM

Once a su?icient quantity of the desired protein has been
obtained, it may be used for various purposes. One use of the

protein or polypeptide is the production of antibodies speci?c

Strains include, for example, BL21 (DE3) (Studier et al.,
Meth. Enzymol, 185260-89 (1990)).
BL21 (DE3) bacteria as described above (provided by
Novagen as part of the pET expression kit). The lacZ gene
(-galactosidase) is expressed in the pET-System as described

Guide to Protein Puri?cation, Methods in Enzymology, Vol.
182 (1990). If the protein is secreted, it can be isolated from
the supernatant in Which the host cell is groWn; otherWise, it
can be isolated from a lysate of the host cells.

propyl-D-thiogalactoside (IPTG), and the T7 RNA poly
merase transcribes any target plasmid containing a functional
T7 promoter, such as pET-28b, carrying its gene of interest.

substantially pure product, i.e., 80, 95, or 99% free of cell
component contaminants, as described in Jacoby, Methods in

45

for binding. These antibodies may be either polyclonal or
monoclonal, and may be produced by in vitro or in vivo
techniques Well knoWn in the art. Monoclonal antibodies to
epitopes of any of the peptides identi?ed and isolated as
described can be prepared from murine hybridomas (Kohler,
Nature, 25 6:495 (1975)). In summary, a mouse is inoculated
With a feW micrograms of protein over a period of tWo Weeks.
The mouse is then sacri?ced. The cells that produce antibod
ies are then removed from the mouse’s spleen. The spleen
cells are then fused With polyethylene glycol With mouse
myeloma cells. The successfully fused cells are diluted in a

microtiter plate and groWth of the culture is continued. The
amount of antibody per Well is measured by immunoassay
methods such as ELISA (Engvali, Meth. Enzymol, 70:419
(1980)). Clones producing antibody can be expanded and
further propagated to produce protein antibodies. Other suit
able techniques involve in vitro exposure of lymphocytes to
the antigenic polypeptides, or alternatively, to selection of
libraries of antibodies in phage or similar vectors. See Huse et

al., Science, 246:1275-128 1 (1989). For additional informa
tion on antibody production see Davis et al., Basic Methods in

MolecularBiology, Elsevier, N.Y., Section 21-2 (1989). Such
50

antibodies are particularly useful in diagnostic assays for
detection of variant protein forms, or as an active ingredient in

a pharmaceutical composition.

EDTA (STE buffer). Cells are then centrifuged at 2000><g for
20 minutes at 4° C. Wet pellets are Weighed and froZen at —80°

Example 1

C. until ready for protein puri?cation.
A variety of methodologies knoWn in the art can be used to

purify the isolated proteins (Coligan et al., CurrentProtocols
in Protein Science, John Wiley & Sons (1995)). For example,

55

pCB6+ vector, pCB6+Par-4, pCB6+_Zip and 163 (Par

the froZen cells can be thaWed, resuspended in buffer and
ruptured by several passages through a small volume microf
luidiZer (Model M-1 105, Micro?uidics International Corp.,

NeWton, Mass.). The resultant homogenate is centrifuged to
yield a clear supernatant (crude extract) and, folloWing ?ltra

60

?cients calculated from amino acid content (Perkins, Eur J.

4DCTH) Were described previously (J ohnstone et al., (1996).
pSV(gal Was a gift from Brett Spear, University of Kentucky.
The RelA luciferase reporter system composed of Gal4
luciferase (Gal4Luc) plasmid (that contains four Gal4 con
sensus DNA binding sites derived from the Saccharomyces
cerevisiae located upstream of luciferase reporter gene), and

tion, the crude extract is fractioned over columns. Fractions
are monitored by absorbance at OD280 nm and peak fractions

may be analyZed by SDS-PAGE.
The concentrations of puri?ed protein preparations are
quanti?ed 15 spectrophotometrically using absorbance coef

Construction of Par-4 Deletion Mutants

Gal4RelA plasmid (containing the yeast Gal4 DNA binding
65

domain fused to the transactivation domain (TA1) of RelA)
Were both from Dr. A. BaldWin (University of North Carolina

at Chapel Hill, Chapel Hill, NC). The GFP cloning plasmids

US 7,786,275 B2
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pcDNA3.1/CTGFPTOPO and pcDNA3.1/NTGFPTOPO

histochemical studies localized Par-4 to both the cytoplasm
and nucleus of prostate cells but exclusively to the cytoplasm
of most tissues and nonprostatic cells. To determine the pre
cise relationship betWeen Par-4 localization and the induction
of apoptosis, a broad panel of transformed and non-trans

Were from Invitrogen Life Technologies, CA.
Par-4 (SEQ ID NO: 1) as a template, followed by ligation
in pcDNA3.1/CTGFPTOPO and then left in the GFP plasmid
or digested With XbaI and KpnI and subcloned into pCB6+.

Polyclonal antibodies for Par-4, NFkB (p65/RelA) and Fas
Were obtained from Santa Cruz Biotechnology, Inc., Calif.
The anti-GFP rabbit polyclonal Was from Torrey Pine

formed cells Was transiently transfected With GFPPar-4 or
GFP vector for control, and the transfectants Were studied for

Biolabs., CA. Terminal deoxynucleotide transferasemediated
dUTPbiotin nick end labeling (TUNEL) enzyme and label

microscopy. These experiments included NIH 3T3 Ras, PC3

Were purchased from Roche Molecular Biochemicals, IN.
The propidium iodide Was from Clonetech, CA. and the
Sepharose G protein Was from Amersham Pharmacia Bio

ptosis induction by Par-4; LNCaP, PrE, PrS and NIH 3T3
parental cells that Were resistant to Par-4; and LNCaP

tech., NJ.

IGFBP5 (an isogenic derivative of LNCaP), MDA MB2b,

intracellular localization of Par-4 or apoptosis by confocal
and DUl45 that Were previously shoWn to be sensitive apo

and LAPC4 that had not been previously tested. Representa
tive examples of nuclear versus cytoplasmic expression and
susceptibility to apoptosis are shoWn in FIG. 1 (A and B). It

Example 2
In vitro Activity of Par-4 Mutants on Cancer Cells

Androgen independent prostate cancer cells PC3 or

Was noted that Par-4 nuclear presence correlated With its
20

DUl45, androgen dependent prostate cancer cells LNCaP,
normal primary prostatic cells PrE or PrS, NIH 3T3 ?broblast
cells and NIH 3T3 Ras transformed ?broblast cells are knoWn

in the art. Androgen dependent prostate cancer cells LAPC4
Were from Charles SaWyers (University of California at Los
Angeles, Calif.) and MDA PCa 2b Were from Nora Navone

25

ability to induce apoptosis (See FIG. 1 and Table 1). Par-4 Was
detected in the nucleus and cytoplasm in androgen indepen
dent prostate cancer cells PC3, DUl45, LNCaP derived cells
LNCaP/IGFBPS, and Rastransformed NIH 3T3 cells. All of
these cell lines Were also sensitive to apoptosis induction by
Par-4 (See Table 1, FIG. 1). HoWever, Par-4 Was strictly

cytoplasmic in the apoptosis-resistant androgen dependent

(MD. Anderson Cancer Center, Tex.). Androgen independent

prostate cancer cells LNCaP, LAPC4 and MDA 2b, mouse

prostate cancer cells LNCaP IGFBP5, Which represent an

immortalized ?broblast NIH 3T3 cells, and primary prostate
epithelial cells PrE or primary prostate stromal cells PrS (See
Table 1). Coexpression of dominant negative FADD or RelA,
Which inhibits Par-4 induced apoptosis, did not prevent Par-4
from translocation to the nucleus, suggesting that nuclear

isogenic derivative of LNCaP cells prepared by stable trans
fection With IGFBP5 expression construct, Were provided by
Martin Gleave (Vancouver General Hospital, British Colum

30

bia, Canada). Immortalized human prostate epithelial cells
PZHPV7, and the head and neck cancer cells SQ20B and
SCC66 Were from Mansoor Ahmed, (University of Ken
tucky). The human lung cancer cells A549, H157, H838 and
H460 Were from John Yannelli (Internal Medicine Depart
ment, University of Kentucky). The human breast cancer cells
MCF7 and MDA 231 Were from GuoMin Li (Pathology,

entry preceded apoptosis by Par-4.
35

putative nuclear localization sequences, NLSl (amino acid
2025) and NLS2 (amino acid 137153) that are conserved in

University of Kentucky). The immortalized breast epithelial
cells MCFlOa Were from Johnson Lombardi (Georgetown
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University). Immortalized human endothelial cells HMEC
Were from Mariana Karakashian (University of Kentucky).
Cells Were transiently transfected With the indicated plas

mid constructs by using lipofectamine plus (from Invitrogen
Life Technologies, CA) folloWing the manufacturer’s proto

45

human, rat and mouse Par-4. To delineate the relationship
betWeen Par-4 entry into the nucleus and induction of apop
tosis, Par-4 derivatives Were prepared that lacked the NLS
sequences (See FIG. 2A). PC3 cells Were transiently trans
fected With these constructs and examined for nuclear entry,

inhibition of NFkB transcription activity or apoptosis. Con
structs DNLSl shoWed nuclear entry, Whereas DNLS2,
Which lacked an intact NLS2 domain, failed to translocate to
the nucleus. This suggests that NLS2 is a functional nuclear
localization sequence. Moreover, loss of DNLS2 but not

col. Cells Were harvested after 48 hours, and Whole cell

lysates Were subjected to Western blot analysis by using the

Par-4 polyclonal antibody (from SantaCruz Biotechnology,
Inc., CA), or luciferase and bgalactosidase assays as previ

ously described) to quantify and normalize RelA activity.

It Was discovered that NLS2, but not NLS 1, is essential for
nuclear entry. The 332 amino acid protein Par-4 has tWo

DNLSl abrogated the ability of Par-4 to inhibit NFkB tran
50

scription activity and induce apoptosis in PC3 cells (See FIG.

Cells Were transfected With the appropriate plasmid con
struct. After ?xing they Were subjected to indirect immunof

2B). These ?ndings indicated that an intact NLS2 sequence
Was essential for nuclear entry of Par-4, and that the ability to

luorescence using secondary antibody conjugated With the

inhibit NFkB transcription activity and to induce apoptosis

?uorescent dye Alexa Fluor 488 (green) from Molecular
Probes, Inc. For localization and apoptosis studies, nuclei

55

Were stained With propidium iodide (PI) or 4',6'

diamidino2phenylindole hydrochloride (DAPI) for 20 min

correlated With nuclear entry of Par-4.
The leucine zipper domain of Par-4 is not essential for
apoptosis. Other domains of Par-4 Were sought Which are

utes after cell ?xation.

essential for apoptosis. The C-terminal leucine zipper domain

Cells plated in chamber slides Were transiently transfected
With untagged or GFP tagged Par-4 or its derivatives. Apop
tosis Was determined by using TUNEL assay and DAPI stain

of Par-4 is required for sensitization of Par-4 resistant cells to
60

ing. The cells expressing untagged protein Were visualized by
staining With antiPar-4 antibody folloWed by DAPI staining.
Apoptotic nuclei Were determined among transfected cells as

described previously.
The results indicate that nuclear translocation of Par-4

correlates With susceptibility to apoptosis. Previous immuno

65

apoptosis and for binding to all currently knoWn partners of
Par-4 including WT1, zPKC, p62 and Dlk. Transient trans
fection of a mutant lacking the leucine zipper domain (DZip)
in PC3 cells resulted in direct induction of apoptosis (See
FIG. 3E.) To further characterize the C-terminus of Par-4,
various C-terminal deletion mutants Were prepared and stud

ied for nuclear localization, inhibition of NFkB transcription
activity and apoptosis in PC3 cells. All C-terminal mutants of

US 7,786,275 B2
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Par-4 had a tendency to translocate preferentially to the

137195 but not by 137190 (See Table 2). Neither Par-4 nor
137195 induced apoptosis in the primary normal or immor

nucleus (See FIG. 3B), Which suggests that the leucine zipper
domain itself may prevent the nuclear translocation of the
protein. As seen in FIGS. 3C and 3D), NFkB transcription

talized cells (See Table 2).

activity and apoptosis Were differentially affected by the

TABLE 1

extent of the C-terminal deletions. Par-4 mutants DZip and

1204 inhibited NFkB transcription activity and induced apo
ptosis. HoWever, mutants 1185 and 1163 neither inhibited

Correlation between nuclear translocation and susceptible to

apoptosis by Par-4.

NFkB transcription activity nor did they induce apoptosis.
Moreover, the ability to induce Fas tra?icking to the cell
membrane in these mutants correlated With their ability to

induce apoptosis. These experiments indicated that the amino
acids doWnstream of 204, including the leucine zipper
domain, Were dispensable for apoptosis by Par-4, and that
binding to the partner proteins via the leucine zipper domain
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Previously, NLS2 Was identi?ed as the most critical

sequence for nuclear localization and apoptosis induction. To
further con?rm the importance of NLS2, tWo N-terminal

Par-4

PC-3

Was not essential for apoptosis induction or inhibition of

Identi?cation of the Core Domain of Par-4

Par-4

DU145

NFkB transcriptional activity by Par-4.
Example 3

Cytoplasmic Apoptosis by

Par-4

deletion constructs 137332 Were constructed and 148332

With either an intact NLS2 or a disrupted NLS2, respectively
(See FIG. 4A). When PC3 cells Were transfected With these
constructs, 137332 but not 148332, Was translocated to the

“LNCaP IGFBP5 is an isogenic derivative ofLNCaP cells.

30 bSensitive: 50-75% ofthe transfected cells undergo apoptosis.

nucleus (See FIG. 4B) and induced apoptosis. This suggested

L‘Resistant: <10% ofthe transfected cells undergo apoptosis.

that NLS2 Was critical for Par-4 function, and that the N-ter
minus of Par-4 Was not required for Par-4 nuclear entry and

apoptotic functions.

TABLE 2
35

To de?ne the minimal domain of Par-4 essential for apop
tosis, additional constructs Were made that began With the
intact NLS2 domain at the amino terminus and With various

137-195 mutant selectively kills cancer cells.

Apoptosis Apoptosis Apoptosis

deletions upstream of amino acid 204 (FIG. 4C). Transient
transfection of PC3 cells indicated that 137195, but not

Cancer
40

137190, inhibited NFkB transcription activity and induced
apoptosis (See FIGS. 4D and 4E). Moreover, co-transfection
of 137195 With dnFADD inhibited apoptosis (See FIG. 4G),

Cells

Sensitive to PC-3
DU145
LNCaP
MDA MB
Resistant to HMECd

indicating that similar to full length Par-4, the 137195 core

domain induced apoptosis by activation of the Fas prodeath
pathWay together With inhibition of NFkB transcriptional
activity. Thus, these ?ndings identi?ed 137195 as the mini

45
Immor-

mal core domain of Par-4 that Was essential and suf?cient to

induce apoptosis in PC3 cells.
The core domain of Par-4 induces apoptosis speci?cally in

talized

50

cancer cells but not in normal cells. To determine Whether

tate cancer cells but not in normal cells (See FIG. 5A). These
data suggested the presence of an inhibitory domain in the
C-terminus of Par-4 and that its deletion alloWed 137195 to be
functional in cells resistant to the apoptotic action of full

prostatic origin, Were induced to undergo apoptosis by

—

MDA 2b

—

MCF-7f

-

PA-HPV-7

—

PrS

—

PrE

—

MCFl Oag

—

|+

55 Eestrogen-independent breast cancer cell line.
festrogen-dependent breast cancer cell line.
gimmortalized breast epithelial cell lines.

60

length Par-4. In vieW of this expanded target range of 137195,

tant cancer cells, regardless of Whether or not they Were of

LAPC-4

l

C — re?ects apoptosis in <10% ofthe transfected cells for all the constructs regardless ofthe
cancer or normal cell background.
uman microvascular endothelial cells.

the susceptibility of a broad panel of cancer and primary
normal or immortalized cells to apoptosis by Par-4 or 137195
Were studied, by using 137190 as a control. These experi
ments indicated that both Par-4 susceptible and Par-4 resis

—

b + re?ects apoptosis in 25-35% ofthe transfected cells.

exclusively in androgen independent prostate cancer cells, a
panel of androgen dependent or independent prostate cancer
cells and primary normal cells Were tested. 137195 induced

-

LNCaP

‘1 + re?ects apoptosis in 50-75% ofthe transfected cells.

similar to Par-4, the core domain 137195 induced apoptosis

apopto sis in both androgen independent and dependent pros

Resistant to

|+
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While this invention has been particularly shoWn and
described With references to preferred embodiments thereof,
it Will be understood by those skilled in the art that various
changes in form and details may be made therein Without
departing from the spirit and scope of the invention as de?ned

by the appended claims.
All references discussed above are herein incorporated by
reference in their entirety.
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SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS:

1

<2lO> SEQ ID NO 1
<211> LENGTH: 332
<2l2> TYPE: PRT

<2l3> ORGANISM: Rattus norvegicus
<400> SEQUENCE: 1

Met Ala Thr Gly Gly Tyr Arg Ser Ser Gly Ser Thr Thr Asp Phe Leu
1

5

1O

15

Leu Trp Lys Ala Lys Arg Glu Lys Met Arg Ala Lys Gln Asn Pro Val

Gly Pro Gly Ser Ser Gly Gly Asp Pro Ala Ala Lys Ser Pro Ala Gly
35

4O

45

Pro Leu Ala Gln Thr Thr Ala Ala Gly Thr Ser Glu Leu Asn His Gly
50

55

60

Pro Ala Gly Ala Ala Ala Pro Ala Ala Pro Gly Pro Gly Ala Leu Asn
65

7O

75

8O

Cys Ala His Gly Ser Ser Ala Leu Pro Arg Gly Ala Pro Gly Gly Ser
85

9O

95

Arg Arg Pro Glu Asp Glu Cys Pro Ile Ala Ala Gly Ala Ala Gly Ala
100

105

110

Pro Ala Ser Arg Gly Asp Glu Glu Glu Pro Asp Ser Ala Pro Glu Lys
115

120

125

Gly Arg Ser Ser Gly Pro Ser Ala Arg Lys Gly Lys Gly Gln Ile Glu
130

135

140

Lys Arg Lys Leu Arg Glu Lys Arg Arg Ser Thr Gly Val Val Asn Ile
145

150

155

160

Pro Ala Ala Glu Cys Leu Asp Glu Tyr Glu Asp Asp Glu Ala Gly Gln
165

170

175

Lys Glu Arg Lys Arg Glu Asp Ala Ile Thr Gln Gln Asn Thr Ile Gln
180

185

190

Asn Glu Ala Ala Ser Leu Pro Asp Pro Gly Thr Ser Tyr Leu Pro Gln
195

200

205

Asp Pro Ser Arg Thr Val Pro Gly Arg Tyr Lys Ser Thr Ile Ser Ala
210

215

220

Pro Glu Glu Glu Ile Leu Asn Arg Tyr Pro Arg Thr Asp Arg Ser Gly
225

230

235

240

Phe Ser Arg His Asn Arg Asp Thr Ser Ala Pro Ala Asn Phe Ala Ser
245

250

255

Ser Ser Thr Leu Glu Lys Arg Ile Glu Asp Leu Glu Lys Glu Val Leu
260

265

270

Arg Glu Arg Gln Glu Asn Leu Arg Leu Thr Arg Leu Met Gln Asp Lys
275

280

285

Glu Glu Met Ile Gly Lys Leu Lys Glu Glu Ile Asp Leu Leu Asn Arg
290

295

300

Asp Leu Asp Asp Met Glu Asp Glu Asn Glu Gln Leu Lys Gln Glu Asn
305

310

315

Lys Thr Leu Leu Lys Val Val Gly Gln Leu Thr Arg
325

330

320
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I claim:
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3. An isolated fusion polypeptide comprising a Par-4 frag
ment selected from the group consisting of amino acids
1-204,137-221,137-213,137-198 and 137-195 ofPar-4 pro

1. An isolated rat prostate apoptosis responsive 4 (Par-4)
protein fragment selected from the group consisting of amino
acids 1-204, 137-221, 137-213, 137-198 and 137-195 of the
tein (SEQ ID NO: 1).
4. A pharmaceutical composition for the treatment of can
Par-4 protein (SEQ ID NO: 1) Wherein the Par-4 protein 5
fragment is effective in reducing the siZe of tumors resistant to
cer, comprising an isolated and puri?ed Par-4 protein selected
apoptosis by Par-4.
from the group consisting of amino acids 1-204, 137-221,
2. A method of producing a polypeptide, comprising incu
137-213, 137-198 and 137-195 ofthe Par-4 protein (SEQ ID
bating a host cell comprising a nucleic acid encoding the
NO: 1), and a pharmaceutically acceptable diluent, carrier or
Par-4 protein fragment of claim 1 in operable linkage With a 10 excipient.
promoter under conditions that permit expression of the Par-4

protein fragment.

